Noradrenaline for progressive supranuclear palsy syndromes (NORAPS): a randomised, double-blind, placebo-controlled, crossover Phase IIb clinical trial evaluating the efficacy and safety of oral atomoxetine for treating cognitive and behavioural changes in people with progressive supranuclear palsy syndromes in the UK

Durcan R, Paula H, Ghosh BCP, Street D, High J, McAlister C, Shepstone L, Russell C, Grant K, Igosheva N, Rodgers CT, Jones SP, Ye R, Kobylecki C, Church A, Antoniades C, Marshall V, Passamonti L, Rowe JB.

BMJ Open. 2025 Jul 28;15(7):e099577. doi: 10.1136/bmjopen-2025-099577.

2025

PMID

40730397

https://doi.org/10.1136/bmjopen-2025-099577

PSP

Noradrenaline for progressive supranuclear palsy syndromes (NORAPS): a randomised, double-blind, placebo-controlled, crossover Phase IIb clinical trial evaluating the efficacy and safety of oral atomoxetine for treating cognitive and behavioural changes in people with progressive supranuclear palsy syndromes in the UK